Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
43
datasets available to search
ShareScore release 0.9.0
Dataset results
43 results for “secondary phases”
Data from the NASCENT campaign used in the publications: "Conditions favorable for secondary ice production in Arctic mixed-phase clouds" and "Understanding the history of two complex ice crystal habits deduced from a holographic imager"
<p>This repository contains the data from the Ny‐Ålesund AeroSol Cloud ExperimeNT campaign (NASCENT). This data were used to produce the figures in the two papers:</p> <p>(1) Pasquier, J. T., Henneberger, J., Ramelli, F., Korolev, A.,Wieder, J., Lauber, A., Li, G., David, R. O., Carlsen, T., Gierens, R., Maturilli, M., and Lohmann, U.: Understanding the history of two complex ice crystal habits deduced from a holographic imager, Geophys. Res. Lett., accepted, 2022</p> <p> </p> <p>(2) Pasquier J. T., Henneberger J., Ramelli F., Lauber A., David O. D., Wieder J., Carlsen T., Gierens R., Maturilli M., and Lohmann U.:Conditions favorable for secondary ice production in Arctic mixed-phase clouds, ACP, accepted.</p> <p>More information can be found in the README files.</p> <p> </p> <p>The scripts to reproduced the Figures are available on Zenodo</p> <p>(1) https://doi.org/10.5281/zenodo.7402296</p> <p>(2) https://doi.org/10.5281/zenodo.7407107</p>
Modelling Amorphization and Dissolution of Zr(Fe,Cr)2 Secondary Phase Precipitates in Zircaloys
<p>Data and accompanying paper "Modelling Amorphization and Dissolution of Zr(Fe,Cr)2 Secondary Phase Precipitates in Zircaloys" J. D. Robson, Journal of Nuclear Materials</p>
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
ClinicalTrials.gov study NCT04415073. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
ClinicalTrials.gov study NCT01696084. IPD Sharing: Not stated. Countries: 2. Publications: 8.
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
ClinicalTrials.gov study NCT05607329. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
ClinicalTrials.gov study NCT01922843. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
ClinicalTrials.gov study NCT00715637. IPD Sharing: Not stated. Countries: 23. Publications: 2.
Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase
ClinicalTrials.gov study NCT04522102. IPD Sharing: NO. Countries: 1. Publications: 3.
Application of Digital Twins' Technology in Patients Who Had a Stroke, with Moyamoya Disease and with Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: a Proof of Concept Using
ClinicalTrials.gov study NCT06714097. IPD Sharing: NO. Countries: 1. Publications: 4.
Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation
ClinicalTrials.gov study NCT00360074. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
ClinicalTrials.gov study NCT02994771. IPD Sharing: NO. Countries: 1. Publications: 0.
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): M
ClinicalTrials.gov study NCT03780608. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
ClinicalTrials.gov study NCT02330965. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Molecular distributions of diacids, oxoacids and -dicarbonyls in summer- and winter-time fine aerosols from Tianjin, North China: Emissions from combustion sources and aqueous phase secondary formation
<p>To understand the characteristics and sources of organic aerosols (OA) in North China, we studied diacids, oxoacids and <em>α</em>-dicarbonyls in summer- and winter-time fine aerosols (PM<sub>2.5</sub>) collected from Tianjin. Oxalic (C<sub>2</sub>) acid was found to be the most abundant diacid species, followed by succinic (C<sub>4</sub>), malonic (C<sub>3</sub>) and sebacic (C<sub>8</sub>) acids, respectively. Glyoxylic (wC<sub>2</sub>) was the most abundant oxoacids followed by pyruvic acid. Concentrations of total diacids, oxoacids and <em>α</em>-dicarbonyls in winter were 2~3 times higher than those in summer, but their mass fractions in PM<sub>2.5</sub> were exactly the opposite. On average, total diacids carbon accounted for 2.9% in total carbon and 3.3% in organic carbon (OC) in summer and 1.8% and 2.0%, respectively, in winter. Their contributions to water-soluble OC (WSOC) was almost the same in both seasons (5.5% and 5.3%, respectively). Molecular distributions, mass ratios of selected diacid (C<sub>3</sub>, C<sub>4</sub>, M, F C<sub>6</sub>, Ph and C<sub>9</sub>) species and the linear relations among the selected species (including åC<sub>2</sub>-C<sub>4</sub> and åC<sub>8</sub>-C<sub>12</sub>) and with inorganic markers (K<sup>+</sup> and SO<sub>4</sub><sup>2-</sup>) implied that the diacids and related compounds are mainly originated from coal combustion and biomass burning emissions and produced in the atmosphere by both <em>in-situ</em> photochemical reactions at local scale and aging during long-range transport in both summer and winter. This study revealed that diacids and related compounds and WSOC are increased with increasing SO<sub>4</sub><sup>2-</sup> and they are produced in aqueous phase, implying the need of reduction in oxidants (NO<em><sub>x</sub></em> and SO<sub>2</sub>) emissions to control the water-soluble OA loading over North China.</p>
Repurposing Domperidone in Secondary Progressive MS - A Simon 2-Stage Phase 2 Futility Trial - Table e1: Results of the binary logistic regression model
<p><b>Objective:</b> To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon two-stage design.</p> <p><b>Methods:</b> We enrolled patients in an open-label, Simon two-stage, single-center, phase 2, single-arm futility trial at the Calgary MS Clinic if they met the following criteria: age 18 to 60 years, SPMS, screening EDSS score of 4.0 to 6.5 and screening T25FW of 9 seconds or more. Patients received domperidone 10mg QID for one year. The primary outcome was worsening of disability, defined as worsening of the T25FW performance by 20% or more at 12 months compared to at baseline. This trial is registered with ClinicalTrials.gov, number NCT02308137.</p> <p><b>Results:</b> Between February 13<sup>th</sup>, 2015 and January 3<sup>rd</sup>, 2020, 110 patients were screened, 81 received treatment, 64 completed follow-up, of whom 62 were analysed. The study did not meet its primary endpoint: 22 of 62 (35%) patients experienced significant worsening of disability, which is close to the expected proportion of 40%, and above the pre-defined futility threshold. Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, which may warrant further investigation. Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients.</p> <p><b>Conclusions:</b> Domperidone treatment could not reject futility in reducing disability progression in SPMS. The Simon two-stage trial model may be a useful model for phase 2 studies in progressive MS.</p> <p><b>Classification of Evidence:</b> This study provides Class III evidence that in individuals with secondary progressive multiple sclerosis participating in a futility trial, domperidone treatment could not reject futility in reducing disability progression at 12 months.</p>
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
ClinicalTrials.gov study NCT01532414. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
ClinicalTrials.gov study NCT05543928. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
ClinicalTrials.gov study NCT06041256. IPD Sharing: NO. Countries: 2. Publications: 0.
Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
ClinicalTrials.gov study NCT01739595. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
ClinicalTrials.gov study NCT04040322. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.